SEC Form 4 · accession 0001209191-18-055417
Urovant Sciences Ltd. · UROV
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Keith Katkin
Officer — PEO;CEO-Urovant Sciences,Inc. · Director
Period of report
Oct 15, 2018
Accepted (ET)
Oct 17, 2018 · 6:12 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001740547
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (Right to Buy)F1 | $13.65 | Oct 15, 2018 | A | 99,967 | A | — | Oct 14, 2028 | Common Shares | 99,967 | 99,967 | D |
Explanation of responses
- F125% of the total shares underlying the option shall vest and become exercisable on October 1, 2019; the remaining shares vest in 12 equal quarterly installments thereafter, subject to the Reporting Person providing continuous service to the Issuer through each such vesting date.